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4. SUMMARY IN FINNISH 
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6. REVIEW OF THE LITERATURE 
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6.2 Tumor site, histopathology, and pathogenesis 
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6.2.2 Pathogenesis and intracellular pathways 
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6.2.2.1 HPV-positive OPSCC 
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6.3 Diagnosis and diagnostic methods 
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6.3.2 Tumor evaluation and diagnostics 

%F ;DAFA;9D HJ9;LA;=	 :AGHKA=K 9J= L9C=F >JGEKMKHA;AGMKGJGH@9JQF?=9D 9J=9K
<MJAF? 9F GLGJ@AFGD9JQF?GDG?A;9D 9F< =F<GK;GHA; =P9EAF9LAGF GJ MF<=J
?=F=J9D 9F=KL@=KA9 )9?F=LA; J=KGF9F;= AE9?AF? ).% GJ ;GEHML=J
LGEG?J9H@Q0G>L@=$*9J=9AKH=J>GJE=<JGMLAF=DQ>GJ=N=JQH9LA=FL).%








AK 9 KLJGF? KA?F G> GJGH@9JQF?=9D GJA?AF G> L@= HJAE9JQ LMEGJ 	 0G
K=9J;@>GJ+,/<A9?FGKAK	9$,2
HGKALAN=DQEH@FG<=>AF<AF?AK>GDDGO=<:Q





  25 




GJ :Q <=L=;LAGF G> $,2 !! E.* LJ9FK;JAHLK :Q IM9FLAL9LAN= J=N=JK=
LJ9FK;JAHL9K=
,. I.0
,. 	 	 	 	0@=E9AFHMJHGK=G> 9DD
E=L@G<K AK LG N=JA>Q 9:AGDG?A;9DDQ 9;LAN=$.
$,2 AF LMEGJ LAKKM= K9EHD=K
!9;@ G> L@=K= L=;@FAIM=K @9K ALK GOF KLJ=F?L@K 9F< DAEAL9LAGFK	 KM;@ 9K
<A>>=J=F;=K AFD9:GJ9LGJQ=PH=FK=K9F<<=L=;LAGF9;;MJ9;Q:=LO==F<A>>=J=FL
H9L@GDG?AKLK9F<N9JA9:D=K=FKALANALQ9F<KH=;A>A;ALQD=N=DK		*GF=G>
L@= E=L@G<K AF<ANA<M9DDQ @9K K@GOF KMH=JAGJALQ AF ;DAFA;9D HJ9;LA;= 9K 9
<A9?FGKLA;LGGD>GJ$,2<=L=;LAGF$GO=N=J	;GE:AFAF?<A>>=J=FLE=L@G<K@9K
AEHJGN=< L@= K=FKALANALQ 9F< KH=;A>A;ALQ G> $,2 <=L=;LAGF 	  :ML FG




F=?9LAN= ;GMFL=JH9JLK	 O@A;@ @9K :==F =KL9:DAK@=< AF FME=JGMK
KLM<A=K 
	 	 	  0@=J=>GJ=	 L@=J= 9J= K=N=J9D GF?GAF? LJA9DK
;GFKA<=JAF? LJ=9LE=FL <=
=K;9D9LAGF >GJ $,2






6.3.3.1 p16 immunohistochemistry 
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6.3.3.2 Detection of HPV DNA by PCR 
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6.3.3.3 Detection of HPV mRNA by qRT-PCR 
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Table 1. HPV-detection methods (33, 34, 40, 42, 98, 102) 
Method Methodology Advantages Disadvantages 
p16 IHC Based on the 
overexpression of p16 




DNA PCR Amplification of viral 
DNA determined by 
PCR 
Sensitivity Specificity, risk for 
contamination 









from frozen samples 
DNA ISH DNA detected in tumor 
cell nuclei by ISH 
Specificity Sensitivity 
mRNA ISH Based on direct 
visualization of genes 
E6/E7 
Sensitivity, 
sensitivity,  detects 
transcriptionally 
active HPV 
Lack of comparative 
studies and experience 
Abbreviations: IHC = immunohistochemistry, ISH = in situ hybridization, qRT-PCR = quantitative 
reverse transcriptase-polymerase chain reaction. 

6.4 Staging and treatment 
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Table 2. 7th edition of UICC and AJCC TNM staging of oropharyngeal squamous 
cell carcinoma (109, 110) 
T category T description   
Tx Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Ti Carcinoma in situ 
T1 Tumor <2 cm in greatest dimension 
T2 Tumor >2 cm but ≤4 cm in the greatest dimension 
T3 Tumor size ≥4 cm in the greatest dimension or extension to lingual 
surface of epiglottis 
T4 Moderately/very advanced disease 
T4a Tumor invades the larynx, deep or extrinsic muscle of the tongue, 
medial pterygoid, mandible, or hard palate 
T4b Tumor invades the lateral pterygoid muscle, pterygoid plates, 
lateral nasopharynx, or skull base or encases the carotid artery 
    
N category  N description  
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single ipsilateral lymph node <3 cm in the greatest 
dimension 
N2 (a-c) Metastases >3 cm but ≤6 cm in the greatest dimension in 
ipsilateral, contralateral, or bilateral lymph nodes 
N2a Metastasis in a single ipsilateral lymph node >3 cm but ≤6 cm in 
the greatest dimension 
N2b Metastasis in multiple ipsilateral lymph nodes ≤6 cm in the 
greatest dimension 
N2c Metastasis in bilateral or contralateral lymph nodes  
≤6 cm in the greatest dimension 
N3 Metastasis in lymph node >6 cm in the greatest dimension 
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M category M description  
MX Distant metastases cannot be assessed 
M0 No distant metastases 
M1 Distant metastases 
    
Stage 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage II T2 N0 M0 





















Stage IVC Any T Any N M1 



























Table 3. 8th edition of UICC and AJCC TNM staging of p16-positive 
oropharyngeal squamous cell carcinoma (38, 39) 
T category T description 
(Clinical/Pathologic)    
T0 No evidence of primary tumor 
T1 Tumor <2 cm in greatest dimension 
T2 Tumor > 2 cm but ≤4 cm in the greatest dimension 
T3 Tumor size ≥4 cm in the greatest dimension or extension to  
lingual surface of epiglottis 
T4 Tumor invades the larynx, deep or extrinsic muscle of the  
tongue, medial pterygoid, hard palate, or mandible or beyond 
N category 
(Clinical)  
N description  
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 One or more ipsilateral lymph nodes, each size ≤6 cm   
N2 Contralateral or bilateral lymph nodes, each size ≤6 cm   




Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastases in ≤4 lymph nodes   
N2 Metastases in >4 lymph nodes   
Stage    Stage 
(Clinical) (Pathologic) 
 N0 N1 N2 N3  N0 N1 N2 
T0 NA I II III T0 NA I II 
T1 I I II III T1 I I II 
T2 I I II III T2 I I II 
T3 II II II III T3 II II III 
T4 III III III III T4 II II III 
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Table 4. 8th edition of UICC and AJCC TNM staging of p16-negative 
oropharyngeal squamous cell carcinoma (38, 39) 
T category T description 
TX Primary tumor cannot be assessed 
Tis Carcinoma in situ 
T1 Tumor <2 cm in greatest dimension 
T2 Tumor >2 cm but ≤4 cm in the greatest dimension 
T3 Tumor size ≥4 cm in the greatest dimension or extension to  
lingual surface of epiglottis 
T4 Moderately/very advanced disease 
T4a Tumor invades the larynx, deep or extrinsic muscle of the  
tongue, medial pterygoid, mandible, or hard palate 
T4b Tumor invades the lateral pterygoid muscle, pterygoid plates, 
lateral nasopharynx, or skull base or encases the carotid artery 
N category N description  
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Single ipsilateral lymph node, ≤3 cm and ENE-negative   
N2a Single ipsilateral lymph node, >3 cm/≤6 cm and ENE- 
negative   
N2b Multiple ipsilateral lymph nodes, ≤6 cm and ENE-negative   
N2c Bilateral or contralateral lymph nodes, ≤6 cm and ENE- 
negative   
N3a Metastasis in a lymph node, >6 cm and ENE-negative   
N3b Any ENE-positive lymph node(s) 
Stage  
 N0 N1 N2a,b,c N3a,b 
T1 I III IVA IVB 
T2 II III IVA IVB 
T3 III III IVA IVB 
T4a IVA IVA IVA IVB 
T4b IVB IVB IVB IVB 
ENE = extranodal extension. Clinical/pathologic T and N categories are the same  







6.4.2  Treatment 
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6.4.2.4 Future directions 
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6.5 Prognosis and prognostic factors 
6.5.1 HPV and prognosis 
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6.5.2 Other clinical and molecular prognostic factors 
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6.6 The role of other oncoviruses in OPSCC 
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6.6.1 Epstein-Barr virus 
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6.6.2 Polyomaviruses 
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6.7 Prevention of OPSCC 
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7. AIMS OF THE STUDY 
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8. MATERIALS AND METHODS 
8.1 Study I 
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? :D==<AF?	 O=A?@L DGKK 9F<






GFK=L LG L@= <9L= G> <A9?FGKAK 0@= HJ=K=FLAF? KQEHLGEK	 <MJ9LAGF G>
KQEHLGEK	9F<;DAFA;9D>AF<AF?KO=J=;GEH9J=<LGHKL9LMK9F<;GE:AF=<
H9F<$,2,.KL9LMK





<=L=JEAF=<:Q,.9F<H %$O9KH=J>GJE=< >GJ 9DD LMEGJK!!.O9K








$,2 9F< H KL9LMK 9F< OAL@ ;DAFA;GH9L@GDG?A;9D >9;LGJK %F 9<<ALAGF	 O=
KLM<A=<L@=HJG?FGKLA;AEH9;LG>9DD<=L=;L=<GF;GNAJMK=K:Q=N9DM9LAF?GN=J9DD
KMJNAN9D+/9F< "/
8.4 Study IV 
"GJ /LM<Q %2	  ;GFK=;MLAN= H9LA=FLK <A9?FGK=< OAL@ +,/ AF 9 
Q=9J
H=JAG<:=LO==F9F<O=J==N9DM9L=<,9LA=FLKLJ=9L=<OAL@H9DDA9LAN=
AFL=FL GJOAL@ <AKL9FLE=L9KL9K=K 9L LAE= G>+,/ <A9?FGKAK FO=J=
=P;DM<=<,9LA=FLKOAL@9K=;GF<HJAE9JQ;9F;=J9LLAE=G>+,/<A9?FGKAK
O=J= 9DKG =P;DM<=< F %F 9<<ALAGF	 H9LA=FLK O@G MF<=JO=FL *  9F<
HJAE9JQ LMEGJ J=K=;LAGF 9K 9 HJAE9JQ LJ=9LE=FL EG<9DALQ O=J= =P;DM<=<
FDLG?=L@=J	H9LA=FLKE=LL@=AF;DMKAGF;JAL=JA99F<O=J=LJ=9L=<OAL@
;MJ9LAN= AFL=FL OAL@ GJ OAL@GML ;AKHD9LAF









H#02 9F< F#02 O=J= <=L=JEAF=< >JGE HJ=
LJ=9LE=FL 0 K;9FK L@J==

<AE=FKAGF9DDQ :Q MKAF? 29JA9F !;DAHK=W .0 LJ=9LE=FL HD9FFAF? KQKL=E
N=JKAGFK  9F<  29JA9F)=<A;9D /QKL=EK %F;	 ,9DG DLG	 	 1/





0@= =F<HGAFLK G> L@= /LM<Q %2 O=J= 9K >GDDGOK +/	  "/	 9F< DG;GJ=?AGF9D
;GFLJGD(.
8.5 Study V 
/LM<Q 2 AF;DM<=<  ;GFK=;MLAN= +,/ H9LA=FLK OAL@ 9N9AD9:D= K=JME
K9EHD=K;GDD=;L=<HJGKH=;LAN=DQ9LL@=LAE=G>+,/<A9?FGKAK,9LA=FLKO=J=
H9JLDQ L@= K9E= 9K AF /LM<A=K % LG %%% 9F<O=J= <A9?FGK=<<MJAF? L@= K9E=
H=JAG< G> LAE= DD H9LA=FLK O=J= LJ=9L=< OAL@ ;MJ9LAN= AFL=FL	 KH=;A>A;9DDQ
KMJ?=JQOAL@GJOAL@GMLHGKLGH=J9LAN=.0.0GJOAL@<=>AFALAN=.0OAL@GJ
OAL@GML;@=EGL@=J9HQ$,2KL9LMKO9K9KK=KK=<OAL@L@=;GE:AF=<KL9LMKG>
H %$ 9F<$,2 * ,. AF ;GF;GJ<9F;=OAL@ /LM<Q %%%3= 9AE=< LG










 AEEMFGHGKALANALA=KO=J==N9DM9L=< 9F< K;GJ=<:GL@ AF
LMEGJ 9F< KLJGE9D ;=DDK K=H9J9L=DQ >JGE0):DG;CK0%),
 9F<)),
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8.6 Laboratory analyses 

8.6.1 Tumor sample collection 

"",! +,/ LAKKM= K9EHD=K O=J= ;GDD=;L=< >JGE L@= <9L9:9K= G> L@=
 =H9JLE=FLG>,9L@GDG?Q	$=DKAFCA1FAN=JKALQ$GKHAL9D









 E) *9D	 9F<  E) ! 0	 H$  9F< >J9?E=FL=< :Q HJGL=9K= '




8.6.3 Tissue microarray blocks 

,J=H9J9LAGF G> 0) :DG;CKO9K H=J>GJE=< 9K AF HJ=NAGMK KLM<A=K 	 
0MEGJ LAKKM= K9EHD=K O=J= >AJKL 9FFGL9L=< >GJ KAP 
EE LMEGJ ;GJ=
HMF;LM9L=K0@= ;GJ= HMF;LM9L=KO=J= J=EGN=< >JGE"",! K9EHD=KOAL@ 9
LAKKM= EA;JG9JJ9Q=J ==;@=J %FKLJME=FLK	 /ADN=J /HJAF?	 ) 	 1/ 9F<
AFK=JL=<AFLG9F=OH9J9>>AF:DG;C

8.6.4 HPV detection 

8.6.4.1 p16 immunohistochemistry 










G> AEEMFGKL9AF=< ;9J;AFGE9 ;=DDK K@GO=< HGKALANALQ 9;;GJ<AF? LG 3$+
J=;GEE=F<9LAGFK

8.6.4.2 HPV DNA detection by PCR 

!PL=JF9D)5)59F<AFL=JF9D#,:AG#,HJAE=JKO=J=MK=<
LG <=L=JEAF= $,2  * ?=FGLQH=K 0@= E=L@G<GDG?Q O9K 9K <=K;JA:=<
HJ=NAGMKDQ,JAE=JK=LK9F<>JGEL@=)MDLAHD=P$,2#=FGLQHAF?'ALW
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 /QKL=E	 AG






8.6.4.3 HPV DNA detection by  ISH 

0@= $,2  * %/$ E=L@G< O9K GFDQ MK=< >GJ ,) % AF /LM<Q % 0@=
E=L@G<GDG?Q@9K:==F<=K;JA:=<AF<=L9ADHJ=NAGMKDQJA=>DQ	9$.
$,2
HJG:= 9F< A2%!3 DM= <=L=;LAGF CAL AF 9 =F;@E9JC 40 K=JA=K KL9AF=J
2=FL9F9)=<A;9D/QKL=EK%F;	0MK;GF	JARGF9	1/O=J=MK=<LG<=L=;L
$,2 :Q %/$ >JGE 0) :DG;CK 0@= CAL <=L=;LK L@= >GDDGOAF? $. $,2





8.6.4.4 HPV mRNA detection by ISH 

0@=<=L=;LAGFG>$.
$,2!!E.* LJ9FK;JAHLK :Q %/$O9KH=J>GJE=<
OAL@E9FM9D .*K;GH=W $ .=9?=FL CAL <N9F;=< =DD  A9?FGKLA;K	
%F;	$9QO9J<	0@=HJ=H9J=<0) KHGLKO=J= AF;M:9L=< >GJ @GMJ 9L
V>GDDGO=<:QLJ=9LE=FLOAL@@Q<JG?=FH=JGPA<9K=.*K;GH=W$Q<JG?=F
,=JGPA<=09J?=LJ=LJA=N9DO9KH=J>GJE=<OAL@.*K;GH=W09J?=L.=LJA=N9D
.=9?=FLK 9F< L@= K=;LAGFK O=J= LJ=9L=< OAL@ HJGL=9K= @Q<JA<AR9LAGF
.*K;GH=W ,JGL=9K= ,DMK >GJ EAFML=K 9L V 0@= HJ=H9J9LAGF O9K
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8.6.5 Detection of EBV and polyomaviruses 


































3’ 0@= K9E= E=L@G<GDG?Q @9K :==F MK=< AF HJ=NAGMK
KLM<A=K	





%/$  =L=;LAGF 'AL  9CG	 #DGKLJMH	  =FE9JC LG <=L=;L !!.K
!!.9F<!!.>JGE0)KDA<=K0@=K9E=E=L@G<GDG?Q@9K:==FMK=<
AF 9 HJ=NAGMK KLM<Q  0@= 0) KDA<=K O=J= LJ=9L=< OAL@ !GKAF 9F<
IM9EGMFL 9CG9>L=JAF;M:9LAGF3==N9DM9L=<L@=LMEGJ9F<KLJGE9D;=DDK
>JGE 0) KDA<=K K=H9J9L=DQ :Q LOG J=K=9J;@=JK .=AB9
.9F<TF J9<Q 9F<
&99F9 $9?KLJUE E:A?MGMK ;9K=K O=J= J=
K;GJ=< 0@= K;GJAF? J=KMDLK G>
!!.O=J=9KK=KK=<9K>GDDGOKF=?9LAN=
	EAD<HGKALANALQHGKALAN=;=DDK
78	 EG<=J9L= HGKALANALQ 
 HGKALAN= ;=DDK 78	 9F< KLJGF? HGKALANALQ
HGKALAN=;=DDK78

8.6.5.3 Detection of polyomaviruses 

 *G>HGDQGE9NAJMK=K&2	'2	9F</2O9K<=L=;L=<:QIM9FLAL9LAN=
I,. .G;@=	 (A?@L Q;D=J 	 .G;@=  A9?FGKLA;K	 .G;@= )GD=;MD9J




3′ and JCTAGP2 5′

000 # ### 0 000 #00 000 0
3′. 0@= HJAE=JK >GJ '2 O=J=
BKVTAG1 5′
00#0#0##0#0#0
3′ and BKVTAG2 5′

##0####00##0###00
3′. The primers for SV40 were 
SVTAGP1 5′
00#000####000#










8.6.6 Methodology of TIMP-1 and MMP-8 

8.6.6.1 Immunohistochemistry and immunological methods 





1/ O9K MK=< 9K 9 HJAE9JQ 9FLA:G<Q >GJ 0%),
 9F9DQKAK "GJ
AEEMFG@AKLG;@=EA;9D 9F9DQKAK G>)),



















8.6.6.2 Serum analyses 









8.7 Statistical analyses 
DD KL9LAKLA;9D 9F9DQK=K O=J= H=J>GJE=< OAL@ %) /,// /L9LAKLA;K  %)	







G> FGJE9DDQ <AKLJA:ML=< ;GFLAFMGMK N9JA9:D=K :=LO==F LOG AF<=H=F<=FL
?JGMHK@A
KIM9J=<9F<"AK@=J’K=P9;LL=KLKO=J=MK=<LG;GEH9J=;9L=?GJA;9D












 K=JME ;GF;=FLJ9LAGFK O=J= EG<A>A=< :Q DG?9JAL@EA;
LJ9F>GJE9LAGFKLG9NGA<HGKALAN=KC=OF=KK.=;=AN=JGH=J9LAF?;@9J9;L=JAKLA;
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.+ ;MJN=K 9F< 5GM<=F AF<=P K=FKALANALQKH=;A>A;ALQ












8.8 Ethical considerations 
DDKLM<Q<=KA?FK>GDDGO=<L@=?MA<=DAF=K9F<D=?AKD9LAGFG>L@= =;D9J9LAGFG>





H9JLA;AH9L=< AF /LM<Q 2 0@AK AF;DM<=< H=JEAKKAGF LG MK= HJAE9JQ +,/







9.1 Detection of HPV by different methods in OPSCC  
(Study I) 
%F/LM<Q%	O=AFN=KLA?9L=<L@=K=FKALANALQ9F<KH=;A>A;ALQ9F<L@=HGKALAN=9F<












Table 5. Sensitivity, specificity, positive predictive value, and negative predictive value 
of all methods when tested against p16 IHC  
XmRNA ISH (total) DNA ISH (PM I) DNA PCR (PM II) 
Sensitivity 93.4 86.3 83.5 
Specificity 92.4 95.3 89.1 
PPV 95.5 96.2 94.8 
NPV 89.0 83.5 69.5 
Abbreviations: NPV = negative predictive value; PM = patient material; PPV = positive 
predictive value. XDetection of HPV mRNA for PM I and PM II was combined. 
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p16+/mRNA ISH- (PM I) 9 1 8   
p16+/mRNA ISH- (PM II) 6   1 5 
p16-/mRNA ISH+ (PM I) 5 2 3   
p16-/mRNA ISH+ (PM II) 5   2 3 
Abbreviations: N = number of patients; PM = patient material; ISH = in situ hybridization; PCR = 
polymerase chain reaction. HPV DNA for PM I was detected by ISH and for PM II by PCR. Reproduced 















9.2 Presenting symptoms and signs of HPV-positive and 
HPV-negative OPSCC and the presence of EBV and 
different polyomaviruses in OPSCC (Studies II-III) 
/LM<Q %% >G;MK=< GF L@= HJ=K=FLAF? KQEHLGEK 9F< GL@=J ;DAFA;9D >9;LGJK G>
$,2
HGKALAN= 9F< $,2















HGKALAN= $,2 *H +,/ 0@AK KQEHLGEO9K G:K=JN=<
KA?FA>A;9FLDQEGJ=G>L=FO@=F;GEH9J=<OAL@H9LA=FLKOAL@<GM:D=

F=?9LAN= $,2  *
H
 +,/ FQ KGJL G> H9AF AF L@=
GLGJ@AFGD9JQF?GDG?A;9D 9J=9 KM;@ 9K KGJ= L@JG9L	 G<QFGH@9?A9	 9F< GL9D?A9




LG H9J9DD=D KQEHLGEKOAL@ L@=$,2<GM:D=
HGKALAN= ?JGMH DD H
HGKALAN=
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Table 7. Presenting symptoms and time delay in diagnosis of 105 OPSCC patients divided by tumor 





HPV-/p16+ HPV-/p16- HPV+/p16+ vs. 
HPV-/p16- 
OR (95% CI) 
All p16+ vs. 
HPV-/p16- 
OR (95% CI) 
N (total) 49 21 35   
Symptom      




   Pain 19 (38.8%) 7 (33.3%) 21 (60.0%) n.s. 0.38  
(0.16–0.87)* 
   Dysphagia/ 
   globus 
4 (8.2%) 3 (14.3%) 6 (17.1%) n.s. n.s. 
   Any other 3 (6.1%) 3 (14.3%) 2 (5.7%) n.s. n.s. 
**Diagnostic 
delay in months  
2.8 (1–18) 2.0 (1–36) 3.0 (1–63) n.s. n.s. 
*P<0.05, **the time from symptom onset to OPSCC diagnosis (range). Abbreviations: N=number of 
patients; OR = Odds ratio; n.s = nonsignificant. Reproduced and slightly modified with permission from 













AF;DM<AF? $,2	 !2 9F< HGDQGE9NAJMK=K &2	 '2	 9F< /2 O=J=














O9K >GMF< AF  LMEGJ K9EHD=K  9F< O9K HJ=K=FL AF L@= KLJGE9D
DQEH@G;QL=K;DGK=LGL@=AFN9KAN=>JGFLG>LMEGJ:MLFGL<AJ=;LDQAFL@=LMEGJ






Table 8. Relation of p16 and HPV in all viruses detected 
 p16+ p16-  P HPV+  HPV- P* 
 n (%) n (%)  n (%)  n (%)  










EBV DNA+ 27 (84.4) 5 (15.6) 0.136 24 (75.0)  8 (25.0) 0.045 
EBV DNA- 90 (71.4) 36 (28.6)  70 (55.6)  56 (44.5)  
EBER+  36 (83.7) 7 (16.3) 0.080 32 (74.4)  11 (25.6) 0.026 
EBER- 69 (69.7) 30 (30.3)  54 (54.5)  45 (45.5)  
JCV DNA+ 18 (81.8) 4 (18.2) 0.370 15 (68.2)  7 (31.8) 0.371 
JCV DNA- 99 (72.8) 37 (27.2)  79 (58.1)  57 (41.9)  
BKV DNA+ 34 (73.9) 12 (26.1) 0.980 27 (58.7)  19 (41.3) 0.896 
BKV DNA- 83 (74.1) 29 (25.9)  67 (59.8)  45 (40.2)  
SV40 DNA+ 0 (0.0) 1 (100.0) 0.259 0 (0.0)  1 (100.0) 0.405 
SV40 DNA- 117 (74.5) 40 (25.5)  94 (59.9)  63 (40.1)  
Abbreviations: n = number of patients. P = P-value. P-values <0.05 are bolded. *= Statistical significance 
when HPV DNA+/p16+ group is compared with a group of other combinations of HPV DNA and p16. 






0.<9,  15,6,8( #(0&1'(' 5/$..  (:24(55,10 ,0 6+( 5641/$.
.;/2+1&;6(5 &.15( 61 6+( 67/14 ,08$5,8( )4106 9+,6( 0$44195  &$.( %$4
length and magnification were 50 μm and x250, respectively. Reproduced 
$0' 5.,*+6.; /1',),(' )41/ 6+( 14,*,0$. 8(45,10 6+$6 +$5 %((0 57%/,66('
$42<0(6$.7027%.,5+('4(57.65

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$,2 O9K L@= GFDQ NAJMK L@9L <AKLAF;LDQ KLJ9LA>A=< H9LA=FLK AFLG LOG <AK=9K=
=FLALA=K :Q ;DAFA;GH9L@GDG?A;9D >9;LGJK )9D= K=P O9K HJ=<GEAF9FL AF :GL@












HJ=K=FL=< OAL@ <AK=9K= =PL=FKAGF LG ;=JNA;9D DQEH@ FG<=K 9L L@= LAE= G>
<A9?FGKAK 9F< L@=EGKL ;GEEGF LMEGJ KAL=O9K LGFKAD %F 9<<ALAGF	 LMEGJ
?J9<=O9K KA?FA>A;9FLDQ @A?@=J 9F< ;DAFA;9D KL9?= DGO=J 9;;GJ<AF? LG L@=L@
=<ALAGF O@=F ;GEH9J=< OAL@ $,2









































Table 9. Demographic and tumor-related factors according to HPV and EBER status (Study III) 
Variable HPV+* HPV-** P EBER+ EBER- P 
N 94 (59.5) 64 (40.5)  43 (30.3) 99 (69.7)  
Mean age 60.8 62.1 0.400 62.5 61.0 0.360 
Sex   0.033   0.663 
   Male 77 (81.9) 43 (67.2)  32 (74.4) 77 (77.8)  
   Female 17 (18.1) 21 (32.8)  11 (25.6) 22 (22.2)  
Smoking   <0.001   0.723 
    Non-smoker  33 (35.1) 10 (15.6)  13 (30.2) 27 (27.3)  
    Ex-smoker 39 (41.5) 10 (15.6)  14 (32.6) 28 (28.3)  
    Current smoker 22 (23.4) 44 (68.8)  16 (37.2) 44 (44.4)  
Heavy alcohol use   0.001   0.419 
    None 52 (72.2) 24 (40.0)  17 (56.7) 51 (57.3)  
    Former 6 (8.3) 13 (21.7)  6 (20.0) 10 (11.2)  
    Current 13 (19.4) 23 (38.8)  7 (23.3) 28 (31.5)  
T class   0.925   0.049 
    T1-T2                     61 (64.9) 42 (65.6)  33 (76.7) 59 (59.6)  
    T3-T4                     33 (35.1) 22 (34.4)  10 (23.3) 40 (40.4)  
N class   0.002   0.087 
     N0                         9 (9.6) 18 (28.1)  4 (9.3) 21 (21.2)  
     N+           85 (90.4) 46 (71.9)  39 (90.7) 78 (78.8)  
Stage                            <0.001   0.069 
    I-II                          75 (79.8) 32 (50.0)  34 (79.1) 63 (63.6)  
    III-IV 19 (20.2) 32 (50.0)  9 (20.9) 36 (36.4)  
Tumor site   <0.001   0.002 
    Tonsil 69 (73.4) 26 (40.6)  36 (83.7) 50 (50.5)  
    Base of tongue 24 (25.5) 18 (28.1)  4 (9.3) 33 (33.3)  
    Soft palate 1 (1.1) 15 (23.4)  2 (4.7) 12 (12.1)  
    Posterior wall 0 (0) 5 (9.5)  1 (2.3) 8 (4.0)  
Grade   <0.001   0.346 
    I                              0 (0) 4 (6.3)  0 (0) 4 (4.0)  
    II                             7 (7.4) 21 (32.8)  6 (14.0) 19 (19.2)  
    III                           87 (92.6) 39 (60.9)  37 (86.0) 76 (76.8)  
Treatment   0.273   0.265 
    RT/CRT 61 (64.9) 36 (56.3)  24 (55.8) 65 (65.7)  
    Sx +- RT/CRT 33 (35.1) 28 (43.8)  19 (44.2) 34 (34.3)  
Abbreviations: CRT = chemoradiotherapy, N+ = extend to local lymph nodes, P = P-value, RT = 
radiotherapy, Sx = surgery. Chi-square test was used for cross tabulation and Fisher’s Exact Test when 
needed. P-values <0.05 are bolded. Percentages may not add up to 100 because of rounding. *Tumors 
that were p16 positive and HPV DNA positive were classified as HPV+. **The remaining HPV-
DNA/p16 combinations were considered HPV-. Reproduced and slightly modified from the original 
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9.3 The prognostic impact of HPV, EBV, and 
polyomaviruses in OPSCC (Study III) 
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P-values of subgroup comparisons: a vs. b, p = 0.936; a vs. c, 2		; a vs. d, p = 0.105; 
b vs. c, p = 		
; b vs. d p = 		




































































































































































P-values of subgroup comparisons: a vs. b, p = 0.966; a vs. c, 2		; a vs. d, p = 0.069; 
b vs. c, p = 		
; b vs. d p = 		
; c vs. d, p = 0.512.
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9.4 pGTV and nGTV as prognostic markers in p16-positive 










F=?9LAN= H9LA=FLK F#02 K@GO=< HJG?FGKLA;
KA?FA>A;9F;= O@=F +/ 9F< (. 9EGF? :GL@ H
HGKALAN= 9F< H
F=?9LAN=




Table 10. Multivariate analysis of tumor volume and TNM classification evaluating overall survival, 
disease-free survival, and locoregional control according to p16-positive and p16-negative OPSCC 
 p16-positive patients  p16-negative patients 
 P-value HR 95% CI  P-value HR 95% CI 
OVERALL 
SURVIVAL 
       
pGTV 0.336 1.0 0.99–1.02  0.020 1.02 1.00–1.04 
nGTV 0.965 1.0 0.98–1.02  0.027 1.02 1.00–1.04 
T class 0.857 0.9 0.27–2.99  0.096 4.27 0.77–23.57 
N class 0.130 2.8 0.74–11.07  0.150 3.28 0.65–16.52 
Stage 0.060 3.2 0.95–11.17  0.046 9.86 1.05–93.03 
DISEASE-FREE 
SURVIVAL 
       
pGTV 0.364 1.0 0.99–1.02  0.106 1.01 0.99–1.03 
nGTV 0.005 1.0 1.01–1.03 0.022 1.02 1.00–1.04 
T class 0.825 0.8 0.30–2.59 0.368 1.85 0.49–7.03 
N class 0.361 1.8 0.50–6.64 0.366 1.88 0.48–7.44 
Stage 0.059 2.8 0.96–8.18 0.185 2.62 0.63–10.93 
LOCOREGIONAL 
CONTROL 
      
pGTV 0.839 1.0 0.96–1.05 0.162 1.01 0.99–1.03 
nGTV 0.007 1.0 1.01–1.05 0.017 1.02 1.00–1.04 
T class 0.740 1.3 0.26–6.60 0.350 2.12 0.44–10.17 
N class 0.805 1.3 0.15–11.42 0.117 3.63 0.73–18.19 
Stage  0.290 2.3 0.47–12.14 0.139 3.82 0.650–22.58 
All variables were calculated in separate multivariate models where age and gender were adjusted. 
pGTV and nGTV are continuous variables. T class, N class, and stage are dichotomous variables. P-
values <0.05 are bolded. Reproduced and slightly modified with permission from Elsevier. 
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9.5 Association of TIMP-1 and MMP-8 with prognosis in 
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Table 11. Multivariate analysis of overall survival according to HPV-positive and HPV-negative 
OPSCC patients 
Variable HPV-positive patients  HPV-negative patients 
 HR 95% CI P-value  HR 95% CI P-value 
Age 1.1 0.9–1.2 0.119  1.0 0.9–1.1 0.249 
Smoking   0.016    0.399 
   Ex-smoker vs. never 3.0 0.3–30.0 0.347  2.7 0.2–35.4 0.451 
   Current vs. never 14.5 1.7–127.6 0.016  3.1 0.6–16.6 0.176 
Stage        
    III-IV vs. I-II                 1.7 0.3–10.5 0.562  8.7 1.5–50.6 0.017 
TIMP-1 serum level 1.1 0.1–12.1 0.958  14.7 1.8–117.4 0.011 
P-values <0.05 are bolded. Age, smoking, stage, and TIMP-1 were adjusted as all had a statistically 
significant association with OS in univariate analysis. Reproduced and slightly modified with 
permission from Springer. 
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10.1 High-risk E6/E7 mRNA ISH is an excellent method 
to detect transcriptionally active HPV in OPSCC 
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10.2 Presenting symptoms and signs differ significantly 
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10.3 Polyomaviruses are detectable in OPSCC and 
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10.4 Large pGTV and nGTV are associated with poor 
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10.5 Elevated serum levels of TIMP-1 are associated 
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10.6 Study strengths and limitations 
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10.7 Concluding remarks and future prospects  
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